Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Spectranetics (SPNC): Any info? -- Ignore unavailable to you. Want to Upgrade?

To: mahler_one who wrote (55)	5/4/2004 1:36:06 PM
From: EACarl	Read Replies (1) \| Respond to of 60

Hello "mahler_one", Well, I don't want you to be stuck here talking to yourself! LOL Yes, it was unfortunate that all we got was a short intraday pop, and are now about where we were before the approval. However, SPNC should now be a company with rapidly increasing sales and hopefully the earnings to go with it! Being as the market is not now fond of tech (PS, I am also a fellow GGNS holder), one would think a non-cyclical med-tech growth company like SPNC would be attractive. I guess we'll have to get a better feel for the numbers here before a fair valuation call can be made. I saw the numbers from the press release about the ~500 units initial shipment (at about ~$1500 per I think), but obviously the important piece of the equation is re-order rates. The 200,000 patients "could benefit" mentioned isn't much to go on. Do you have any "feel" or model for projecting the sales potential and/or growth rate here? I'd love to find some data to support that SPNC is still "cheap" ;-) Regards, Eric.